whom medical treatment failed) and the early surgical group, the misdiagnosed cases being excluded in both groups. In this comparison, the hospital stay is, on average, 12 days shorter for the early surgical group (see Table 3 ).
Conclusion
More results are needed for a valid conclusion. There has been no increased mortality or morbidity with early surgery for acute cholecystitis as compared with the traditional management. Early surgery means a shorter hospital stay and there is early relief of pain. REFERENCES Hepatic tumours derive their main blood supply from the hepatic artery, and ligation of this artery has been shown to result in selective necrosis of the tumour (Mori et al. 1966 ). The concept of treating hepatic tumours by infusion chemotherapy is attractive, as a high concentration of the cytotoxic agents can be achieved locally. Furthermore, when fluorinated pyrimidines are used systemic reactions are mild or absent, as these drugs are detoxified in the liver (Sullivan et al. 1964) . This paper reports our experience with hepatic artery ligation and infusion chemotherapy in the treatment of 17 patients with advanced malignancy of the liver. 'Address for correspondence: A Cuschieri chM, Department of Surgery, University of Liverpool, PO Box 147, Liverpool, L69 3BX
Patients and Methods
Patients with advanced and symptomatic hepatic malignancy were accepted for treatment. The series included 5 patients with inoperable primary liver tumours (hepatocellular carcinoma 3, cholangiocarcinoma 2) and 12 with massive secondary hepatic involvement (colorectal 8, gastric 1, adrenal 1, unknown 2). The series consisted of 11 male and 6 female patients, with an age range of 38 to 66 years.
Investigations included standard liver function tests (serum bilirubin, proteins, alkaline phosphatase and alanine aminotransferase), hmmoglobin estimation and full blood counts, which were repeated at frequent intervals during the period of cytotoxic therapy. Five patients had a serum bilirubin of more than 5.0 mg/100 ml prior to surgery. Hepatic scintiscans with technetium-99m-labelled sulphur colloid were performed before and after surgery in 12 patients. In a few cases laparoscopy and target biopsy of the tumour was undertaken before operation. Operative technique: A laparotomy was performed via a right paramedian approach. The extent of tumour deposits within the peritoneal cavity was assessed and a wedge biopsy of the tumour was taken. In the absence of extensive extrahepatic dissemination, the first part of the duodenum was mobilized superiorly to expose the gastroduodenal artery, which was then traced to its origin from the hepatic artery. A Teflon (polytetrafluoroethylene) catheter was next introduced into this artery via the gastroduodenal. The hepatic artery was then tied in continuity proximal to the origin of the right gastric, which was also ligated (Fig 1) . The position of the catheter tip was checked by hepatic arteriography or by injection of 40.0 ml methylene blue. The latter results in an intense discoloration of the tumour if the catheter is in the right position. The hepatic and gastroduodenal arteries were then doubly ligated around the Teflon catheter, which was brought out through a separate stab wound and connected to a chemofusor (Burn & Gains 1973) . Intra-arterial infusion with 5-fluorouracil was commenced at the time of surgery. A cholecystectomy or ligation of the cystic artery as reported by Stehlin et al. (1974) was not performed. Cytotoxic therapy: The output volume of the chemofusor used in this study was 5.0 ml every 24 hours, which is equivalent to a maximum daily dose of 250 mg 5-fluorouracil. Since then a modified form of the same chemofusor has become available, and this delivers 10.0 ml every GDA, gastroduodenal artery. HA, hepatic artery. TC, Teflon catheter catheter from the hepatic artery. Six patients received an additional course of methotrexate (500 mg over 10 days) at the end of the six weeks. Folinic acid (6.0 mg four times daily) was administered intramuscularly to these patients to minimize the systemic side-effects of methotrexate.
Assessment: An objective response to treatment was defined as clinical or liver-scan evidence of tumour regression accompanied by improved liver function tests. Palliation was considered to be worth while in patients who obtained relief of pain for three or more months.
Results
The procedure was tolerated well by most patients. There was one postoperative death. This patient went into a convulsive coma a few hours after surgery and died soon after that. Unfortunately no post-mortem was performed. Transient derangement of liver function accompanied by fever and leukocytosis was common. Thus the total WBC which averaged 7800/mm3 s.d.±+2250 before surgery rose to 16 700±3330 after 7-10 days in patients with metastatic disease. The maximal rise in the serum bilirubin, from 2.4 mg/100 ml s.d.±1.80 to 3.8+2.0, occurred within the first week of surgery, as did the elevation in the serum alanine aminotransferase activity. This rose from a preoperative level of 122.0 iu/100 ml s.d.+91.95 to 1070.6+547.25. The above changes had largely subsided within 14 days of surgery. Apart from these changes, no serious systemic side-effects were seen in any of the patients during therapy with 5-fluorouracil. Pancytopenia was encountered in one patient during methotrexate infusion. However, vomiting, malaise and abnormal elevation of the transaminases were seen in 2 patients after 6 weeks of intra-arterial infusion with 5-fluorouracil; for this reason, a rest period of 1-2 weeks is now given, during which the chemofusor is filled with isotonic saline before further cytotoxic infusion is recommenced. Six patients developed increased liver tenderness in the first postoperative week.
In the group of patients with metastatic disease, 6 showed an objective response to treatment and experienced relief of pain. Three patients with metastatic disease died during the first four weeks of therapy and the remaining 3 patients continued to deteriorate slowly. The mean survival in months was 9.0 s.d.+±5.1 for the 6 patients who showed a good response and 2.2 months +2.5 for the other patients with metastatic disease.
In the 4 patients in whom chemofusor therapy had to be abandoned for technical reasons, the mean survival was 2.9 months s.d. +2.5. These patients received less than 5.0 g 5-fluorouracil. The best results for metastatic disease were obtained in the 4 patients who were infused with 10.0 g 5-fluorouracil over a period of 6 weeks, followed by 50.0 mg methotrexate daily for 10 days. This group had a mean survival of 12.25 months s.d.+t3.86.
The results obtained in patients with primary hepatic tumours are summarized in Table 1 . In one patient with cirrhosis of the liver and hepatoma a marked regression of the tumour was seen as a result of the treatment, and this patient survived for 18 months. Two patients in this group died suddenly during the fourth and fifth weeks of treatment. The cause of death was found Cholangiocarcinoma 5-fluorouiracil (6 g) Poor 2.5 months at autopsy to be massive tumour pulmonary embolism. In both cases post-mortem showed involvement of the hepatic veins by the primary tumour, which had extensive areas of necrosis.
Discussion
There have been several favourable reports in recent years on the treatment of advanced primary and metastatic liver tumours by hepatic artery ligation and infusion chemotherapy (Murray-Lyon et al. 1970 , Fortner et al. 1973 , Stehlin et al. 1974 ). In the present series an objective response was obtained through this form of treatment in 50 % of cases with symptomatic secondary hepatic malignancy, and this was accompanied by relief of pain.
The results in cases with primary hepatic tumours are difficult to interpret. Although a dramatic result was obtained in one patient with hepatoma, 2 out of 5 patients died of massive tumour pulmonary embolism 4 and 5 weeks after initiation of therapy. In both cases extensive necrosis of the primary tumour was found at post-mortem. It could be argued that pulmonary embolism by tumour was secondary to infusion chemotherapy. Tumour pulmonary embolism, however, is also known to occur in untreated advanced hepatoma.
It must be stressed that prolonged infusion chemotherapy via the hepatic artery with 5fluorouracil was not accompanied by any serious side-effects apart from transient pyrexia and elevation of the serum bilirubin and transaminases during the first 10 days of therapy. Symptoms and signs of a chemical hepatitis can develop, however, after 4-6 weeks of infusion chemotherapy and if this treatment is to be prolonged, it is recommended that rest periods be introduced at strategic intervals.
The results of the present series indicate that a successful outcome is more likely if treatment is prolonged beyond 4 weeks; this may be due to the relatively slow doubling time of metastatic tumours, as reported by Collins et al. (1956) . Some degree of hepatic decompensation with hyperbilirubinmmia is very common in patients with advanced symptomatic malignancy. We have therefore included in our series jaundiced patients who tolerated the procedure well. Indeed, 2 out of 5 patients with a preoperative serum bilirubin of more than 5.0 mg/100 ml responded well to treatment. We do not therefore regard the presence of jaundice as a contraindication to this form of therapy, especially as this would exclude a substantial number of patients with symptomatic hepatic malignancy.
It is not possible to draw any definite conclusions from this small series. The results obtained are encouraging, however, as in other retrospective reports on the outcome of this form of therapy. These reports indicate that hepatic artery ligation and prolonged infusion chemotherapy may impart worth-while palliation in patients with advanced hepatic malignancy, and therefore stress the need for a controlled clinical trial to prove the efficacy or otherwise of this form of treatment.
